Data / Form D filings / ALDAGEN INC
ALDAGEN INC: Form D filings
ALDAGEN INC, a biotechnology company in Durham, NC, filed 5 Form D notices with the SEC between 2009 and 2012. The latest, on January 13, 2012, reports $585,004 sold of a $645,004 offering to 13 investors.
Find out what ALDAGEN INC does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 2810 MERIDIAN PARKWAY SUITE 148, Durham, NC, 27713
- Phone
- (919) 484-2571
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506
- SEC identifier (CIK)
- 1128188
The full lists. Form D filings in North Carolina: 984 rows, $49.20, or the new rows each week for $19 a month. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jan 13, 2012 | Amendment | $645,004 | $585,004 | $60,000 | 13 | Sep 16, 2011 | sec.gov |
| Oct 3, 2011 | New notice | $525,004 | $525,004 | $0 | 11 | Sep 16, 2011 | sec.gov |
| Jun 23, 2011 | New notice | $1,080,377 | $1,080,377 | $0 | 11 | Jun 20, 2011 | sec.gov |
| Nov 24, 2009 | Amendment | $10,000,000 | $7,287,902 | $2,712,098 | 10 | Oct 22, 2009 | sec.gov |
| Oct 27, 2009 | New notice | $10,000,000 | $7,287,902 | $2,712,098 | 10 | Oct 22, 2009 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| MARTIN MURPHY | Director | |
| B. JEFFERSON CLARK | Director | |
| RICHARD KENT | Director | |
| LYLE A. HOHNKE | Executive Officer, Director | |
| WILLIAM JEFFERSON EVANS | Director | |
| JAMES A. HINSON | Executive Officer | |
| WILLIAM A. BROOKE | Director | |
| DENNIS A. DOUGHERTY | Director | |
| JOEL KIMBROUGH | Director | |
| EDWARD A. FIELD | Executive Officer |
Other biotechnology companies in North Carolina that filed recently
- Toggle Bio $200,000 · Oct 6, 2026
- Swift Cardiovascular, Inc. $810,000 · Sep 24, 2026
- Aclarity Genomics, Inc. $4.6 million · Sep 2, 2026
- Aer Therapeutics, Inc. $3 million · Aug 19, 2026
Every Form D from the week of Jan 9, 2012 · All recent filings in North Carolina · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what ALDAGEN INC reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.